Kosh Agarwal
0000-0002-4754-828X
404 papers found
Refreshing results…
Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues
Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients
Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens
Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”
Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection
Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry
96 weeks treatment of tenofovir alafenamide vs . tenofovir disoproxil fumarate for hepatitis B virus infection
HepCARE: A tool enabling the identification, assessment and management of viral hepatitis. An integrated approach to the patient journey
HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
Does Detectable Hbcrag or Pre-Genomic HBV RNA in Serum at Time of Nucleoside Analogue Therapy Withdrawal Predict Severe ALT Flare Outcome and the Need to Restart Therapy?
HBsAg Is Still Detected By Ultrasensitive HBsAg Test in Patients Post-Liver Transplantation on Long-Term Monotherapy with Nucleos(t)Ide Analogue after Hbig Withdrawal
Aetiology of delirium post liver transplant and the effect on inpatient length of stay
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C
Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything
Hepatitis B Core-Related Antigen Is a Better Marker Than HBsAg for Discriminating between Chronic HBV Infection and Chronic Hepatitis B in a HBeAg-negative European Cohort
Missing publications? Search for publications with a matching author name.